HC Wainwright & Co. Reiterates Buy on TransCode Therapeutics, Maintains $3 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Emily Bodnar reiterated a Buy rating on TransCode Therapeutics (NASDAQ:RNAZ) and maintained a $3 price target.
April 03, 2024 | 4:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
TransCode Therapeutics received a reiterated Buy rating and a maintained $3 price target from HC Wainwright & Co.
The reiteration of a Buy rating and maintenance of a $3 price target by a reputable analyst firm like HC Wainwright & Co. can positively influence investor sentiment and potentially lead to an increase in stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90